Loading...

Tenax Therapeutics, Inc.

TENX•NASDAQ
HealthcareBiotechnology
$6.05
$-0.10(-1.65%)

Tenax Therapeutics, Inc. (TENX) Stock Overview

Explore Tenax Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for TENXStats details for TENX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$20.00
Average$20.00
High$20.00

Company Profile

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

CEO

Mr. Christopher T. Giordano

Employees

4

Headquarters

ONE Copley Parkway, Chapel Hill, NC

Founded

1994

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.